Pharos iBio Co., Ltd. (KOSDAQ:388870)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,120.00
+130.00 (1.86%)
Last updated: Jun 12, 2025

Pharos iBio Statistics

Total Valuation

Pharos iBio has a market cap or net worth of KRW 85.70 billion. The enterprise value is 72.94 billion.

Market Cap 85.70B
Enterprise Value 72.94B

Important Dates

The next estimated earnings date is Thursday, August 14, 2025.

Earnings Date Aug 14, 2025
Ex-Dividend Date n/a

Share Statistics

Pharos iBio has 12.95 million shares outstanding. The number of shares has increased by 3.87% in one year.

Current Share Class 12.95M
Shares Outstanding 12.95M
Shares Change (YoY) +3.87%
Shares Change (QoQ) +0.19%
Owned by Insiders (%) 32.78%
Owned by Institutions (%) 2.72%
Float 8.70M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio 5.45
P/TBV Ratio 5.61
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -6.89
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -7.72

Financial Position

The company has a current ratio of 11.90, with a Debt / Equity ratio of 0.01.

Current Ratio 11.90
Quick Ratio 11.28
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF -0.01
Interest Coverage -2,547.88

Financial Efficiency

Return on equity (ROE) is -51.35% and return on invested capital (ROIC) is -36.74%.

Return on Equity (ROE) -51.35%
Return on Assets (ROA) -35.06%
Return on Invested Capital (ROIC) -36.74%
Return on Capital Employed (ROCE) -77.57%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -39.97% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -39.97%
50-Day Moving Average 6,702.60
200-Day Moving Average 8,197.30
Relative Strength Index (RSI) 46.37
Average Volume (20 Days) 48,916

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

Revenue n/a
Gross Profit -17.94M
Operating Income -12.21B
Pretax Income -10.59B
Net Income -10.59B
EBITDA -11.40B
EBIT -12.21B
Earnings Per Share (EPS) -818.86
Full Income Statement

Balance Sheet

The company has 12.85 billion in cash and 84.60 million in debt, giving a net cash position of 12.76 billion or 985.73 per share.

Cash & Cash Equivalents 12.85B
Total Debt 84.60M
Net Cash 12.76B
Net Cash Per Share 985.73
Equity (Book Value) 15.71B
Book Value Per Share 1,213.71
Working Capital 12.54B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.77 billion and capital expenditures -672.02 million, giving a free cash flow of -9.44 billion.

Operating Cash Flow -8.77B
Capital Expenditures -672.02M
Free Cash Flow -9.44B
FCF Per Share -729.45
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Pharos iBio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.87%
Shareholder Yield n/a
Earnings Yield -12.35%
FCF Yield -11.02%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1